Neural stem cell injection for treating senile dementia and Parkinson's disease

Abstract

The invention relates to a nerve stem cell injection made from retina pigment epithelial cell, to treat paralysis agitans, wherein said injection at least comprises 3*106 nerve stem cells of human hRPE, while said nerve stem cells are cultivated from retina pigment epithelial cells. And its production comprises that: (1), separating and cultivating cells, that separating the hRPE cells, mixing uniformly to prepare single cell suspension; (2), hRPE cell cultivation and generation that digests original cultivation liquid, ending digestion, blowing and beating to form cell suspension, eccentrically filtering and removing the upper clear liquid, adding cultivating substrate, to disperse and form cell suspension, filtering with cell screen, transferring cell into cultivating bottle, generating to at least fifth generation; (3), adding common salt into hRPE nerve stem cell, to prepare cell suspension injection.

Description

technical field [0001] The invention relates to a neural stem cell injection, especially a neural stem cell injection derived from human retinal pigment epithelial cells (human retinal pigment epithelial cells, hRPE) and used for treating Parkinson's disease and Alzheimer's disease, belonging to biomedicine field. Background technique [0002] Parkinson's disease (Parkinson's disease PD) is a common degenerative disease of the central nervous system in middle-aged and elderly people. The current clinical treatment of Parkinson's disease is based on the oral administration of DA prodrug levodopa, but this drug is effective at first, but the efficacy will decline after long-term use, and cause a series of movement disorder complications. Surgical treatment is mainly based on the pallidus and thalamus, but the recurrence rate is high after surgery. The above-mentioned method belongs to symptomatic treatment and cannot reverse the degeneration of DA neurons, and the replacemen...

AI Technical Summary

Problems solved by technology

Analyzing the reasons, patients in the substantia nigra cell transplantation treatment group after transplantation of 4 donor embryos had significantly improved compared with those before treatment at 6 months and 9 months after transplantation, but then the condition deteriorated and the immunosuppressant cyclosporine (cyclosporine) was completely eliminated. ) at the same time, it is speculated that the decline in the efficacy of cell transplantation therapy is consistent with the occurrence of immune reactions

Images